ProCE Banner Activity

Navigating a New Therapeutic Era for HCC: Expert Review of New Agents and Guideline Recommendations

Multimedia
Watch this CME-certified on-demand Webcast of a CCO symposium in Chicago to gain expert perspectives on the evolving treatment landscape for HCC, with a focus on first-line and second-line systemic therapy for advanced/unresectable disease.

Released: July 25, 2019

Expiration: July 23, 2020

No longer available for credit.

Share

Faculty

Thomas A. Abrams

Thomas A. Abrams, MD

Institute Physician
Director, Liver Tumor Center
Dana-Farber Cancer Institute
Boston, Massachusetts

R. Kate Kelley

R. Kate Kelley, MD

Associate Professor
Division of Hematology and Oncology
University of California, San Francisco
San Francisco, California

Stacey Stein

Stacey Stein, MD

Assistant Professor of Medicine
Yale University School of Medicine
Section of Medical Oncology
New Haven, Connecticut

Provided by

Provided by National Comprehensive Cancer Network.
ProCE Banner

Supporters

This activity is supported by educational grants from:

Bayer Healthcare Pharma

Eisai

Partners

NCCN

ProCE Banner

Learning Objectives

  • Explore first-line treatment options for individual patients with advanced HCC, considering the available clinical evidence, known agent toxicity/tolerability profiles, expert recommendations, and patient preferences
  • Apply clinical evidence and expert recommendations to select optimal treatment for patients with HCC that has progressed on or after 1 or multiple lines of therapy
  • Plan therapeutic strategies that optimize the sequence of therapies to provide the best outcome to patients with HCC
  • Counsel patients to help them understand their treatment options and to be proactive, knowledgeable participants in their care
  • Employ effective collaborative strategies to ensure the best possible application of the latest HCC treatment approaches
  • Become familiar with the design of ongoing clinical trials for novel HCC treatment strategies and counsel appropriate patients about availability and participation

Faculty Disclosure

Primary Author

Thomas A. Abrams, MD

Institute Physician
Director, Liver Tumor Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Thomas A. Abrams, MD, has disclosed that he has received consulting fees from Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Ipsen, and Merck and funds for research support from Lilly.

R. Kate Kelley, MD

Associate Professor
Division of Hematology and Oncology
University of California, San Francisco
San Francisco, California

R. Kate Kelley, MD, has disclosed that she has received consulting fees from Agios, AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech/Roche, and Target PharmaSolutions and funds for research support (to her institution) from Agios, AstraZeneca, Bayer, Bristol-Myers Squibb, Exelixis, Lilly, MedImmune, Merck, Novartis, QED, and Taiho.

Stacey Stein, MD

Assistant Professor of Medicine
Yale University School of Medicine
Section of Medical Oncology
New Haven, Connecticut

Stacey Stein, MD, has disclosed that she has received consulting fees from Bayer, Bristol-Myers Squibb, Eisai, Genentech, and Merck.

Staff Disclosure

Staff

Joy Curzio, PhD

Editorial Contributor

Joy Curzio has disclosed that her spouse has ownership interest in Advaxis, Editas, and OncoSec.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.